| __timestamp | Catalent, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 334800000 | 612613000000 |
| Thursday, January 1, 2015 | 337300000 | 650773000000 |
| Friday, January 1, 2016 | 358100000 | 619061000000 |
| Sunday, January 1, 2017 | 402600000 | 628106000000 |
| Monday, January 1, 2018 | 462600000 | 717599000000 |
| Tuesday, January 1, 2019 | 512000000 | 964737000000 |
| Wednesday, January 1, 2020 | 577900000 | 875663000000 |
| Friday, January 1, 2021 | 687000000 | 886361000000 |
| Saturday, January 1, 2022 | 844000000 | 997309000000 |
| Sunday, January 1, 2023 | 831000000 | 1053819000000 |
| Monday, January 1, 2024 | 935000000 | 1053819000000 |
Cracking the code
In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry giants: Takeda Pharmaceutical Company Limited and Catalent, Inc., from 2014 to 2024. Over this decade, Takeda's SG&A expenses have consistently dwarfed those of Catalent, with Takeda's 2023 expenses reaching approximately 1.05 trillion, a staggering 1,200% higher than Catalent's 935 million. Notably, Catalent has shown a steady increase in SG&A expenses, growing by nearly 180% from 2014 to 2024, reflecting its expansion efforts. Meanwhile, Takeda's expenses surged by about 72% during the same period, indicating strategic investments in global operations. This financial snapshot underscores the contrasting scales and strategies of these pharmaceutical leaders, offering insights into their operational priorities and market positioning.
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and argenx SE
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Axsome Therapeutics, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Halozyme Therapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Veracyte, Inc. Trends and Insights
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Celldex Therapeutics, Inc.
Catalent, Inc. and Lantheus Holdings, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Catalent, Inc. vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Catalent, Inc. and TG Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Catalent, Inc. and Catalyst Pharmaceuticals, Inc.
Catalent, Inc. vs Wave Life Sciences Ltd.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Catalent, Inc. or Celldex Therapeutics, Inc.
Catalent, Inc. or Xencor, Inc.: Who Manages SG&A Costs Better?